Rituximab in the treatment of diffuse large B-cell lymphoma primary of the lung
摘要：
Diffuse large B-cell lymphoma primary of lung (DLBCL-PL) is a rare presentation of extranodal lymphoma, in most cases chemotherapy-based anthracyclines: CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) has been the treatment, with excellent outcome.The addition of rituximab to CHOP (R-CHOP) has been considered the gold standard in the treatment of nodal DLBCL.Thus, we assess in a large number of cases of DLBCL-PL whether the use of R-CHOP could improve survival in this setting of patients.Forty-two patients with DLBCL-PL, stage IE, age 65 years or younger, were treated with standard R-CHOP, no consolidation radiotherapy or maintenance therapy were considered.They were matched with patients who received CHOP alone to assess efficacy and toxicity.Complete response was observed in 35 patients (83), and 7 patients were considered failure (16).The study has a median follow-up of 42.8 months.Actuarial curves at 5 years showed that progression-free survival was 88 and overall survival was 70 .The results were not statistically different when compared retrospectively with patients who received CHOP alone.Treatment was well tolerated.The addition of rituximab to chemotherapy did not improve outcome in patients with DLBCL-PL.
展开
DOI：
10.1179/1607845412y.0000000031
被引量：
年份：
2013
相似文献
参考文献
引证文献
辅助模式
引用
文献可以批量引用啦~
欢迎点我试用！
